MARKET

DARE

DARE

Dare Bioscience Inc
NASDAQ
0.3199
-0.0274
-7.89%
After Hours: 0.3188 -0.0011 -0.34% 19:53 12/07 EST
OPEN
0.3700
PREV CLOSE
0.3473
HIGH
0.3700
LOW
0.3087
VOLUME
6.80M
TURNOVER
0
52 WEEK HIGH
1.400
52 WEEK LOW
0.2800
MARKET CAP
31.53M
P/E (TTM)
-0.6640
1D
5D
1M
3M
1Y
5Y
FDA Gives Nod To Daré Bioscience's Trial Of Non-Hormonal Treatment For Dyspareunia, Seeks Additional Funding
Fda clears daré bioscience's ind for dare-vva1 as a non-hormonal treatment option for dyspareunia, a symptom of vva associated with menopause. Vva is an inflammation and thinning of the vaginal epithelium.
Benzinga · 12h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers dare bioscience (nasdaq:dare) shares rose 31.1% to $0.46 during thursday's pre-market session. Anixa biosciences shares moved upwards by 20.35%. Cerevel therapeutics hldg shares rose 14.54%. Vanda pharma stock rose 20.04%.
Benzinga · 14h ago
Weekly Report: what happened at DARE last week (1127-1201)?
Weekly Report · 3d ago
Weekly Report: what happened at DARE last week (1120-1124)?
Weekly Report · 11/27 10:13
Daré Bioscience And Premier Research Have Extended Their Partnership Agreement To Continue Providing On An Exclusive Basis Contract Research Organization Services Within The US To Support The Clinical Development Of Daré's Reproductive Health Portfolio
Benzinga · 11/20 13:06
Weekly Report: what happened at DARE last week (1113-1117)?
Weekly Report · 11/20 10:12
Weekly Report: what happened at DARE last week (1106-1110)?
Weekly Report · 11/13 10:08
Daré Bioscience: Strong Financial Health and Promising Product Pipeline Drive ‘Buy’ Recommendation
TipRanks · 11/11 15:25
More
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).

Webull offers Dare Bioscience Inc stock information, including NASDAQ: DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.